pivekimab sunirine
immunogen,bridgebio pharmaceutical
['cadenza', 'pivekimab', 'bridge bio', 'immunogen ']
bcbn feed: immunogen presents updated findings from cadenza trial of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm at eha 2023 congress: waltham, mass. (business wire) immunogen inc. ... #boston #biotech 
Boston Cambridge Biotech Networks: Building a community and providing news and events for the local life science industry. For jobs follow @bcbnjobs